Accueil   Diary - News   All news BIOASTER in collaboration with Janssen and the CRCL

BIOASTER in collaboration with Janssen and the CRCL

BIOASTER announces Hepatitis B Collaboration with Janssen and the Cancer Center of Lyon (CRCL).


Objective of the collaboration: bring a predictive model for the development of novel therapies.



BIOASTER, and Cancer Center of Lyon (CRCL, France) represented by its managing partners INSERM1, CNRS2, UCBL3 and CLB4, have signed a contract with Janssen-Cilag SAS, one of the Janssen Pharmaceutical Companies of Johnson & Johnson to advance the global fight against chronic hepatitis B virus (HBV). The collaboration is jointly coordinated by Janssen France and Johnson & Johnson Innovation.


Read the press release



By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree